Kewaunee Scientific Co. (NASDAQ:KEQU) Director Keith M. Gehl Purchases 403 Shares of Stock

Kewaunee Scientific Co. (NASDAQ:KEQU) Director Keith M. Gehl purchased 403 shares of Kewaunee Scientific stock in a transaction that occurred on Tuesday, March 18th. The stock was purchased at an average cost of $49.00 per share, for a total transaction of $19,747.00. Following the completion of the purchase, the director now owns 17,000 shares of the company’s stock, valued at $833,000. This trade represents a 2.43 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Kewaunee Scientific Price Performance

Shares of NASDAQ KEQU opened at $49.69 on Wednesday. The company has a 50 day simple moving average of $58.16 and a two-hundred day simple moving average of $47.77. Kewaunee Scientific Co. has a fifty-two week low of $30.82 and a fifty-two week high of $71.33. The company has a market capitalization of $142.71 million, a price-to-earnings ratio of 7.87 and a beta of 0.71. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.13 and a current ratio of 2.64.

Kewaunee Scientific (NASDAQ:KEQU) last announced its quarterly earnings data on Wednesday, March 12th. The technology company reported $1.09 earnings per share (EPS) for the quarter. Kewaunee Scientific had a return on equity of 25.83% and a net margin of 9.39%. The business had revenue of $67.17 million during the quarter.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of Kewaunee Scientific from a “buy” rating to a “hold” rating in a report on Friday, March 14th.

Hedge Funds Weigh In On Kewaunee Scientific

Several large investors have recently modified their holdings of the stock. Bank of America Corp DE increased its stake in Kewaunee Scientific by 2,605.9% during the 4th quarter. Bank of America Corp DE now owns 460 shares of the technology company’s stock valued at $28,000 after purchasing an additional 443 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Kewaunee Scientific by 18,000.0% during the third quarter. JPMorgan Chase & Co. now owns 905 shares of the technology company’s stock valued at $30,000 after acquiring an additional 900 shares in the last quarter. IFP Advisors Inc purchased a new position in Kewaunee Scientific in the 4th quarter worth approximately $36,000. Morgan Dempsey Capital Management LLC bought a new position in Kewaunee Scientific in the 4th quarter valued at approximately $106,000. Finally, Barclays PLC purchased a new stake in Kewaunee Scientific during the 3rd quarter valued at $121,000. Hedge funds and other institutional investors own 32.69% of the company’s stock.

Kewaunee Scientific Company Profile

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.